Key clinical point: Patients with psoriatic arthritis (PsA) who received strategic treatment with biological disease-modifying anti-rheumatic drugs (bDMARD) based on peripheral T-lymphocyte phenotyping achieved greater reduction in disease activity than patients who did not undergo phenotyping or bDMARD selection strategy.
Major finding: A significantly higher proportion of patients in the strategic vs standard bDMARD treatment group achieved disease activity of PsA-remission (90.2% vs 67.8%; P = .0132) and minimal disease activity (80.5% vs 60.7%; P = .0464) by month 6.
Study details: Findings are from a real-world, retrospective study that included 97 patients with PsA who received bDMARD for ≥1 year and compared 1-year treatment response between the strategic (n = 41) and standard (n = 56) bDMARD treatment groups.
Disclosures: This work was supported by Research on Rare and Intractable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labor, and Welfare of Japan, and other sources. The authors declared receiving grants, honoraria, speaking fees, or consulting fees from several sources.
Source: Miyagawa I et al. Precision medicine based on the phenotypic differences in peripheral T helper cells in patients with psoriatic arthritis: One year follow-up outcomes. Front Med (Lausanne). 2022;9:934937 (Jul 27). Doi: 10.3389/fmed.2022.934937